Apeloa Pharmaceutical Adjusts Valuation Amid Mixed Financial Performance Signals

Apeloa Pharmaceutical Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects notable shifts in the company's valuation metrics and technical indicators. The stock's valuation has transitioned from a classification of expensive to very attractive, indicating a significant change in its perceived worth relative to its earnings and book value. Key financial metrics such as the P/E ratio stand at 20, while the EV to EBITDA ratio is recorded at 12.23. Additionally, the company boasts a dividend yield of 4.35%, which may appeal to certain segments of the market. On the technical front, the trends have shown a mix of signals. The MACD indicates a mildly bearish stance on a weekly basis, while the monthly perspective leans towards a mildly bullish outlook. Other indicators, such as the KST, reflect a bullish sentiment over both weekly and monthly periods. Despite these adjustments, Apeloa Pharmaceutical has faced challenges, including a decline in net sales and operating profit growth over the past five years. The company reported a significant drop in net sales of 14.55% for the quarter ending September 2025, alongside negative results for two consecutive quarters. For more insights on Apeloa Pharmaceutical Co., Ltd., including the latest Mojo Score and financial trend performance, visit: Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.